3//SEC Filing
667, L.P. 3
Accession 0001144204-15-047532
CIK 0001404644other
Filed
Aug 9, 8:00 PM ET
Accepted
Aug 10, 8:18 AM ET
Size
15.3 KB
Accession
0001144204-15-047532
Insider Transaction Report
Form 3
BAKER JULIAN
10% Owner
Holdings
- 458,665(indirect: See Footnote)
Common Stock
- 3,808,635(indirect: See Footnote)
Common Stock
BAKER FELIX
10% Owner
Holdings
- 3,808,635(indirect: See Footnote)
Common Stock
- 458,665(indirect: See Footnote)
Common Stock
Baker Brothers Life Sciences LP
10% Owner
Holdings
- 458,665(indirect: See Footnote)
Common Stock
- 3,808,635(indirect: See Footnote)
Common Stock
667, L.P.
10% Owner
Holdings
- 3,808,635(indirect: See Footnote)
Common Stock
- 458,665(indirect: See Footnote)
Common Stock
BAKER BROS. ADVISORS LP
10% Owner
Holdings
- 458,665(indirect: See Footnote)
Common Stock
- 3,808,635(indirect: See Footnote)
Common Stock
Baker Bros. Advisors (GP) LLC
10% Owner
Holdings
- 458,665(indirect: See Footnote)
Common Stock
- 3,808,635(indirect: See Footnote)
Common Stock
Footnotes (3)
- [F1]As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 458,665 shares of Common Stock of the Issuer beneficially owned by 667, L.P. ("667") a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
- [F2]As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest 3,808,635 shares of Common Stock of the Issuer beneficially owned by Baker Brothers Life Sciences, L.P. ("Life Sciences") a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
- [F3]Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to 667 and Life Sciences(the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
Documents
Issuer
AQUINOX PHARMACEUTICALS, INC
CIK 0001404644
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001551139
Filing Metadata
- Form type
- 3
- Filed
- Aug 9, 8:00 PM ET
- Accepted
- Aug 10, 8:18 AM ET
- Size
- 15.3 KB